Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | PHASE1 | RECRUITING | 32 | — | — | Jul 1, 2024 | Aug 1, 2028 | Jul 10, 2024 | 1 | China |
An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.
CAR positive T cells levels in peripheral blood after LCAR-HL30 infusion.
CAR positive T cells levels in bone marrow after LCAR-HL30 infusion.
RP2D established through accelerated titration design (ATD) and Bayesian Optimal Interval (BOIN) design.
| Arm | Type | Description |
|---|---|---|
| Chimeric antigen receptor T cells LCAR-HL30 cells | EXPERIMENTAL | Each subject will receive LCAR-HL30 cells. |
| Name | Type | Description |
|---|---|---|
| LCAR-HL30 cells | BIOLOGICAL | Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine |
Inclusion Criteria: 1. Subjects voluntarily participate in clinical research. 2. Aged 18 to 75 years, either sex. 3. Eastern Cooperative Oncology Group (ECOG) score 0-1 (Dose escalation phase). ECOG score 0-2 (Dose expansion period). 4. Histologically confirmed Hodgkin's lymphoma or Anaplastic larg...